SELECTED XGEVA ABSTRACTS
| |
- Effect of denosumab vs. zoledronic acid in patients with castrate-resistant prostate cancer and bone metastases: Subgroup analyses by prior SRE and baseline pain
| |
| (Abstract 4533) Poster Discussion on Saturday, June 4, 2:00 p.m. - 6:00 p.m., E450a
| |
| |
- Prevalence of recognized bone metastases in the U.S. adult population
| |
| (Abstract 1534) Poster on Saturday, June 4, 2:00 p.m. - 6:00 p.m., Hall A
| |
| |
- Denosumab safety and efficacy in giant cell tumor of bone (GCTB): Interim results from a phase II study
| |
| (Abstract 10034) Poster on Sunday, June 5, 8:00 a.m. - 12:00 p.m., Hall A
| |
| |
- Effects of denosumab on pain reduction in giant cell tumor of bone (GCTB): interim phase II study results
| |
| (Abstract 10037) Poster on Sunday, June 5, 8:00 a.m. - 12:00 p.m., Hall A
| |
| |
- A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE)
| |
| (Abstract TPS152) Poster on Monday, June 6, 8:00 a.m. - 12:00 p.m., Hall A
| |
| |
- A single-arm multicenter proof-of-concept study of denosumab to treat hypercalcemia of malignancy in patients who are refractory to IV bisphosphonates
| |
| (Abstract TPS245) Poster on Monday, June 6, 8:00 a.m. - 12:00 p.m., Hall A
| |
| |
SELECTED VECTIBIX ABSTRACTS
| |
- Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer
(mCRC)
| |
| (Abstract 3510) Oral Presentation on Saturday, June 4, 1:00 p.m. - 4:00 p.m., Hall D1
| |
| |
- Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared with FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Results by Eastern Cooperative Oncology Group (ECOG) performance status (PS)
| |
| (Abstract 3567) Poster on Saturday, June 4, 8:00 a.m. - 12:00 p.m., Hall A
| |
| |
- Evaluating the relationship between progression-free survival (PFS) and overall survival (OS) in clinical trials of patients (pts) with metastatic colorectal cancer
(mCRC)
| |
| (Abstract 3617) Poster on Saturday, June 4, 8:00 a.m. - 12:00 p.m., Hall A
| |
| |
- Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181
| |
| (Abstract 3574) Poster on Saturday, June 4, 8:00 a.m. - 12:00 p.m., Hall A
| |
| |
- The relationship between quality of life (QOL) and tumor response in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab (pmab) plus FOLFIRI as first-line therapy: An analysis of study 314
| |
| (Abstract 3634) Poster on Saturday, June 4, 8:00 a.m. - 12:00 p.m., Hall A
| |
| |
- Evaluation of gene mutations beyond KRAS as predictive biomarkers of response to panitumumab in a randomized, phase III monotherapy study of metastatic colorectal cancer
(mCRC)
| |
| (Abstract 3530) Poster Discussion on Monday, June 6, 8:00 a.m. - 12:00 p.m., E450b
| |
| |
SELECTED ARANESP® (darbepoetin alfa) ABSTRACTS
| |
- Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: The LNH03-6B study
| |
| (Investigator Sponsored Abstract 9048) Saturday, June 4, 2:00 p.m. - 6:00 p.m., Hall A
| |
| |
SELECTED PIPELINE ABSTRACTS
| |
- A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses
| |
| (Abstract 3500) Oral Presentation on Saturday, June 4, 4:30 p.m. - 6:00 p.m., Hall D1
| |
| |
- Effect of baseline (BL) biomarkers on overall survival (OS) in metastatic pancreatic cancer (mPC) patients (pts) with ganitumab (GAN, AMG 479) or placebo (P) in combination with gemcitabine (G)
| |
| (Abstract 4041) Poster on Saturday, June 4, 8:00 a.m. - 12:00 p.m., Hall A
| |
| |
- Exposure-response (E-R) analysis to facilitate phase III dose selection for ganitumab (GAN, AMG 479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer
(mPC)
| |
| (Abstract 4049) Poster on Saturday, June 4, 8:00 a.m. - 12:00 p.m., Hall A
| |
| |
- A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer
(LR/MBC)
| |
| (Abstract 544) Poster on Monday, June 6, 1:00 p.m. - 5:00 p.m., Hall A
| |
| |
- An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC)
| |
| (Abstract LBA7512) Poster Discussion on Monday, June 6, 2:00 p.m. - 6:00 p.m., E450a
| |
| | |
| For the latest updates on Amgen's presence at ASCO and other Amgen news, follow us on Twitter @Amgen.
| |
| |
